We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Single-Cell Analysis Provides New Insights into Mitochondrial Diseases

By LabMedica International staff writers
Posted on 24 Aug 2020
Mitochondrial diseases result from failure of mitochondria, specialized compartments within cells that contain their own DNA and produce the energy needed to sustain life. More...
Some of the most challenging mitochondrial disorders arise from mutations in mitochondrial DNA (mtDNA), a high-copy-number genome that is maternally inherited.

These diseases manifest with marked clinical heterogeneity, in part because tissues generally contain a mixture of both non-mutant and mutant mtDNA, a phenomenon called heteroplasmy. Heteroplasmy varies dramatically across family members, tissues, and time and is hypothesized to be shaped by a combination of random drift and selection.

Medical scientists at the Massachusetts General Hospital (MGH, Boston, MA, USA) and their colleagues applied a single-cell genomics technology, mtDNA single-cell assay for transposase-accessible chromatin (ATAC) sequencing, to determine mtDNA heteroplasmy and cell type simultaneously in many thousands of peripheral-blood mononuclear cells (PBMCs) that were obtained from unrelated patients with Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). The team examined mtDNA within different blood cell types from nine individuals with MELAS, one of the most common forms of mtDNA disease associated with brain dysfunction and stroke-like episodes, with a wide range of severity across patients.

The team obtained samples of venous blood at clinical baseline and purified PBMCs from the patients. They stained cells for viability and applied antihuman CD45 antibodies before fixation and performed fluorescence-activated cell sorting (FACS) to exclude dead and non-leukocyte cells (CD45−). The mtDNA single-cell ATAC sequencing libraries were generated by a 10× Chromium Controller and a modified Chromium Single Cell ATAC Library and Gel Bead Kit protocol (10×Genomics, Pleasanton, CA, USA), which was followed by paired-end sequencing with the use of a NextSeq 500 platform (2× 72-bp reads) (Illumina, San Diego, CA, USA).

By using mtDNA single-cell ATAC sequencing, the team generated high-quality sequencing libraries to simultaneously evaluate cell type and heteroplasmy in thousands of individual cells per patient. Using accessible chromatin signatures derived from nuclear genomic reads, they defined cell states using a latent semantic indexing projection of each patient’s data set onto a single-cell reference map of healthy-donor PBMCs that had been generated by a similar single-cell ATAC sequencing protocol. The analysis revealed especially low levels of heteroplasmy in T cells, which play important roles in killing infected cells, activating other immune cells, and regulating immune responses. They also observed this pattern in six additional patients who had heteroplasmic A3243G without stroke-like episodes.

Melissa A. Walker, MD, PhD, a Pediatric Neurologist and senior author of the study, said, “What makes this study unique is that it is, to our knowledge, the first time anyone has been able to quantify the percentage of disease-causing mitochondrial DNA mutations in thousands of individual cells of different types from the same patient, as well as in multiple patients with inherited mitochondrial disease.” The study was published on August 12, 2020 in the New England Journal of Medicine.





New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.